149 related articles for article (PubMed ID: 32220805)
21. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
22. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
23. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.
Kawarada Y; Ganss R; Garbi N; Sacher T; Arnold B; Hämmerling GJ
J Immunol; 2001 Nov; 167(9):5247-53. PubMed ID: 11673539
[TBL] [Abstract][Full Text] [Related]
24. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.
Ballas ZK; Krieg AM; Warren T; Rasmussen W; Davis HL; Waldschmidt M; Weiner GJ
J Immunol; 2001 Nov; 167(9):4878-86. PubMed ID: 11673492
[TBL] [Abstract][Full Text] [Related]
25. Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses.
Kochenderfer JN; Chien CD; Simpson JL; Gress RE
J Immunol; 2006 Dec; 177(12):8860-73. PubMed ID: 17142789
[TBL] [Abstract][Full Text] [Related]
26. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z
Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838
[TBL] [Abstract][Full Text] [Related]
27. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells.
Schirmbeck R; Riedl P; Zurbriggen R; Akira S; Reimann J
J Immunol; 2003 Nov; 171(10):5198-207. PubMed ID: 14607920
[TBL] [Abstract][Full Text] [Related]
28. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
VanOosten RL; Griffith TS
Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
[TBL] [Abstract][Full Text] [Related]
29. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
30. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor.
Yuan S; Qiao T; Chen W
Cancer Biother Radiopharm; 2011 Apr; 26(2):203-8. PubMed ID: 21539452
[TBL] [Abstract][Full Text] [Related]
31. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
[TBL] [Abstract][Full Text] [Related]
32. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
33. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.
Nierkens S; den Brok MH; Roelofsen T; Wagenaars JA; Figdor CG; Ruers TJ; Adema GJ
PLoS One; 2009 Dec; 4(12):e8368. PubMed ID: 20020049
[TBL] [Abstract][Full Text] [Related]
34. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer.
Chuang CM; Monie A; Wu A; Mao CP; Hung CF
Hum Gene Ther; 2009 Apr; 20(4):303-13. PubMed ID: 19272013
[TBL] [Abstract][Full Text] [Related]
35. CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach.
Zhang X; Hu Q; He X; Cui X; Liang Z; Wang L; Deng X; Zhang Z; Sheng W; Han XD
J Nanobiotechnology; 2023 May; 21(1):159. PubMed ID: 37208748
[TBL] [Abstract][Full Text] [Related]
36. Fully phosphorothioate-modified CpG ODN with PolyG motif inhibits the adhesion of B16 melanoma cells in vitro and tumorigenesis in vivo.
Wang X; Wang L; Wan M; Wu X; Yu Y; Wang L
Nucleic Acid Ther; 2013 Aug; 23(4):253-63. PubMed ID: 23848522
[TBL] [Abstract][Full Text] [Related]
37. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.
Sfondrini L; Sommariva M; Tortoreto M; Meini A; Piconese S; Calvaruso M; Van Rooijen N; Bonecchi R; Zaffaroni N; Colombo MP; Tagliabue E; Balsari A
Int J Cancer; 2013 Jul; 133(2):383-93. PubMed ID: 23319306
[TBL] [Abstract][Full Text] [Related]
39. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.
Geary SM; Lemke CD; Lubaroff DM; Salem AK
Cancer Immunol Immunother; 2011 Sep; 60(9):1309-17. PubMed ID: 21626029
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo.
Oh SM; Oh K; Lee DS
J Korean Med Sci; 2011 Oct; 26(10):1270-6. PubMed ID: 22022177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
